Record-breaking Seizure: Over 300,000 Vapes Confiscated in Perth

Aug.14.2023
Record-breaking Seizure: Over 300,000 Vapes Confiscated in Perth
Over 300,000 vapes, worth an estimated $10 million, have been seized from a warehouse in Perth, Australia.

According to a report on the abc.net website on August 14th, Australian health authorities have recently seized a total of 300,000 e-cigarettes worth an estimated $10 million from a warehouse in the northeast of Perth, Western Australia. In addition, over 10 tons of pods were also confiscated. This seizure is said to be the largest of its kind ever recorded in both the state and the country.


Authorities have revealed that over 300,000 e-cigarettes have been discovered, following a sudden operation prompted by a report, according to a statement made by Western Australia's Minister for Health, Amber-Jade Sanderson.


The data for the month of June revealed that the Western Australian Department of Health has filed only one lawsuit against a retailer involved in the illegal sale of nicotine e-cigarettes in the past 12 months. Consequently, the e-cigarette regulatory system implemented by the Western Australian government has faced criticism and scrutiny.


According to the 2014 Pharmacy and Poisons Act, the maximum penalty for selling nicotine e-cigarettes in Western Australia is a personal fine of $45,000 and three years imprisonment, or a company fine of $225,000.


Within the 12 months leading up to June, Western Australia seized 43,000 illegal e-cigarettes and issued dozens of warnings. In May, the Health Department acknowledged that no fines were imposed for illegal possession of e-cigarettes. These devices have been widely sold in stores and through underground online delivery services in Perth. The sale of e-cigarettes without a pharmacist's prescription is illegal.


References:


Over 300,000 vaping devices confiscated from a warehouse in Perth, marking a groundbreaking seizure in Western Australia.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
Philip Morris Japan announced on April 23 at a product briefing that ZYN by IQOS, an oral tobacco pouch previously launched in selected areas, will expand sales in Tokyo. The company said the product will be released progressively from May 11 through IQOS shops, Lawson and other outlets in the city. The launch will include four flavors, each offered in Low and Medium intensity levels, for a total of eight products.
Apr.27 by 2FIRSTS.ai
South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea Expands Tobacco Harmful Components Testing System to Cover Synthetic Nicotine Liquid Vapes
South Korea’s Ministry of Food and Drug Safety said on April 17 that it has additionally designated the International Characterization Research Institute as a tobacco harmful components testing body under the Act on the Management of Tobacco Harmfulness. The institute has research experience in analyzing harmful components in liquid e-cigarettes and has obtained recognition for tobacco-sector ISO 17025 requirements.
Apr.17 by 2FIRSTS.ai
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center said it will apply the same regulations used for conventional tobacco products to all tobacco products, including liquid e-cigarettes, from April 24, while also strengthening public guidance and smoke-free zone management.
Apr.21 by 2FIRSTS.ai